the New York Stock Exchange (the “Separation”).
The Separation was effectuated through a pro-rata dividend distribution on July 2, 2016 of all of the then-outstanding shares of common stock of Fortive Corporation to the holders of common stock of Danaher as of June 15, 2016.
In this Annual Report, the terms “Fortive” or the “Company” refer to either Fortive Corporation or to Fortive Corporation and its consolidated subsidiaries, as the context requires.
Reportable Segments The table below describes the percentage of sales attributable to each of our two segments over each of the last three years ended December 31, 2017.
For additional information regarding sales, operating profit and identifiable assets by segment, please refer to Note 17 to the Consolidated and Combined Financial Statements included in this Annual Report.
## Table 0 ##
Professional Instrumentation Our Professional Instrumentation segment offers essential products, software and services used to create actionable intelligence by measuring and monitoring a wide range of physical parameters in industrial applications, including electrical current, radio frequency signals, distance, pressure, temperature, radiation, and hazardous gases.
Customers for these products and services include industrial service, installation and maintenance professionals, designers and manufacturers of electronic devices and instruments, medical technicians, safety professionals and other customers for whom precision, reliability and safety are critical in their specific applications.2017 sales for this segment by geographic destination were: North America, 50%; Europe, 18%; Asia Pacific, 26%, and all other regions, 6%.
Our Professional Instrumentation segment consists of our Advanced Instrumentation & Solutions and Sensing Technologies businesses.
Our Advanced Instrumentation & Solutions business was primarily established through the acquisitions of Qualitrol in the 1980s, Fluke Corporation in 1998, Pacific Scientific Company in 1998, Tektronix in 2007, Invetech in 2007, Keithley Instruments in 2010, eMaint in 2016, Industrial Scientific in 2017, Landauer in 2017 and numerous bolt-on acquisitions.
Advanced Instrumentation & Solutions Our Advanced Instrumentation & Solutions business consists of: Field Solutions Our field solutions products include a variety of compact professional test tools, thermal imaging and calibration equipment for electrical, industrial, electronic and calibration applications, online condition-based monitoring equipment; portable gas detection equipment, consumables, and software as a service (SaaS) offerings including safety/user behavior, asset management, and compliance monitoring; subscription-based technical, analytical, and compliance services to determine occupational and environmental radiation exposure; and computerized maintenance management software for critical infrastructure in utility, industrial, energy, construction, public safety, mining, and healthcare applications.
These products and associated software solutions measure voltage, current, resistance, power quality, frequency, pressure, temperature, radiation, hazardous gas and air quality, among other parameters.
Typical users of these products and software include electrical engineers, electricians, electronic technicians, safety professionals, medical technicians, network technicians, first-responders, and industrial service, installation and maintenance professionals.
The business also makes and sells instruments, controls and monitoring and maintenance systems used by maintenance departments in utilities and industrial facilities to monitor assets, including transformers, generators, motors and switchgear.
Products are marketed under a variety of brands, including FLUKE, FLUKE BIOMEDICAL, FLUKE NETWORKS, INDUSTRIAL SCIENTIFIC, LANDAUER and QUALITROL.
Product Realization Our product realization services and products help developers and engineers across the end-to-end product creation cycle from concepts to finished products.
Our test, measurement and monitoring products are used in the design, manufacturing and development of electronics, industrial, video and other advanced technologies.
Typical users of these products and services include research and development engineers who design, de-bug, monitor and validate the function and performance of electronic components, subassemblies and end-products, and video equipment manufacturers, content developers and broadcasters.
The business also provides a full range of design, engineering and manufacturing services and highly-engineered, modular components to enable conceptualization, development and launch of products in the medical diagnostics, cell therapy and consumer markets.
Finally, the business designs, develops, manufactures and markets critical, highly-engineered energetic materials components in specialized vertical applications.
Products and services are marketed
McKESSON CORPORATION FINANCIAL REVIEW (Continued) large volume sales of pharmaceuticals primarily to a limited number of large self-warehousing customers whereby we order and subsequently deliver bulk products from the manufacturer to the customers’ warehouses through a central distribution facility.
These sales provide a benefit to our customers in that they can use one source for both their direct store-to-store business and their warehouse business.
Canadian pharmaceutical distribution revenues increased reflecting market growth rates, favorable exchange rates and new business from manufacturers which formerly engaged in direct distribution activities.
On a constant currency basis, revenues from our Canadian operations would have increased approximately 10% in 2005 compared to 2004.
Medical-Surgical Solutions segment distribution revenues increased slightly in 2005 as growth in revenues in the alternative site sector exceeded a decline in revenues in the acute care sector.
Increases in our alternate site sector include revenues of Moore Medical Corporation (“MMC”), which we acquired in the first quarter of 2005.
MMC is an Internet-enabled, multi-channel marketer and distributor of medicalsurgical and pharmaceutical products to non-hospital provider settings.
Revenues for 2004 decreased nominally as increases in our primary and alternate site sectors were more than fully offset by a decline in revenues in the acute care sector.
Declines in our acute care sector reflect the loss of the segment’s largest customer in the third quarter of 2004.
Provider Technologies segment revenues increased in 2005 reflecting greater demand for our clinical applications and imaging technology offerings as well as growth in automation product installations.
Revenues for 2004 decreased reflecting growth in software services and hardware which were fully offset by decreases in sales of non-clinical solutions, longer installation periods required for certain large complex clinical implementations and contracting changes in the segment’s automation business both of which had the effect of delaying revenue recognition.
Gross Profit:
## Table 1 ##
Gross profit increased by 7% in 2005 and 5% in 2004.
As a percentage of revenues, gross profit decreased 37 and 76 basis points in 2005 and 2004.
Gross profit margin decreased primarily reflecting a decline in the Pharmaceutical Solutions segment margin.
Additionally, declines in our gross profit margin were due to a higher proportion of revenues attributable to our Pharmaceutical Solutions segment, which has lower margins relative to our other segments in 2004.
Gross profit was also impacted by a $51.0 million provision for expected contract losses in 2003 within our Provider Technologies segment.
In 2005, gross profit margin for our Pharmaceutical Solutions segment was impacted by: a lower number of and average magnitude of price increases on branded pharmaceuticals in the current year compared to 2004, – pressure on other buy side margins as the industry continues to evolve.
Certain types of vendor product incentives and sources of supply, such as certain inventory purchases in the secondary market, are not available at historical levels to the major distributors, which has the impact of reducing gross margins, – lower selling margins within our U. S.  pharmaceutical distribution business which reflect a higher proportion of revenues attributable to institutional customers, and continued competitive pressures which moderated
McKESSON CORPORATION PART I Item 1.  Business General McKesson Corporation (“McKesson,” the “Company,” the “Registrant,” or “we” and other similar pronouns), is a Fortune 15 corporation providing supply, information and care management products and services designed to reduce costs and improve quality across the healthcare industry.
The Company’s fiscal year begins on April 1 and ends on March 31.
Unless otherwise noted, all references in this document to a particular year shall mean the Company’s fiscal year.
Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (the “Exchange Act”) are available free of charge on our Web site (www.
mckesson.
com under the “Investors — SEC Filings” caption) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (“SEC” or the “Commission”).
Business Segments We conduct our business through three segments.
Through our Pharmaceutical Solutions segment, we are a leading distributor of ethical and proprietary drugs, and health and beauty care products throughout North America.
This segment also manufactures and sells automated pharmaceutical dispensing systems for retail pharmacies, and provides medical management and specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, patient and other services for payors, and software, and consulting and outsourcing services to pharmacies.
Our Medical-Surgical Solutions segment distributes medical-surgical supplies, first-aid products and equipment, and provides logistics and other services within the United States and Canada.
Our Provider Technologies segment delivers enterprise-wide patient care, clinical, financial, supply chain, managed care and strategic management software solutions, automated pharmaceutical dispensing systems for hospitals, as well as outsourcing and other services, to healthcare organizations throughout North America, the United Kingdom and other European countries.
The Company’s strategy is to create strong, value-based relationships with customers, enabling us to sell additional products and services to these customers over time.
Net revenues for our segments for the last three years were as follows:
## Table 2 ##
Pharmaceutical Solutions Our Pharmaceutical Solutions segment consists of the following businesses: Pharmaceutical Distribution, McKesson Canada Corporation, Retail Automation, Payor Group and McKesson Specialty.
We also own an approximately 49% interest in Nadro, S. A.  de C. V.  (“Nadro”), a pharmaceutical distributor in Mexico.
U. S.  Pharmaceutical Distribution.
This business supplies pharmaceuticals and other healthcare related products to customers in three primary customer segments: national and regional retail chains, institutional providers, and retail independent pharmacies.
The U. S.  Pharmaceutical Distribution business operates and serves thousands of customer locations through a network of 28 distribution centers, as well as a master distribution center and a repackaging facility, serving all 50 states.
We invest in technology and other systems at all of our distribution centers to enhance safety, reliability and the best product availability for our customers.
For example, in all of our distribution centers we use Acumax?
Plus, a Smithsonian award-winning technology, which integrates and tracks all internal functions, such as receiving, put-away and order fulfillment.
Acumax?
Plus uses bar code technology, wrist-mounted computer hardware, and
McKESSON CORPORATION FINANCIAL NOTES (Continued) The following table summarizes the activity related to the restructuring liabilities, excluding customer settlement reserves, for the three years ended March 31, 2005:
## Table 3 ##
Accrued restructuring liabilities are included in other liabilities in the consolidated balance sheets.
In connection with the acquisition of MMC in 2005, we recorded $1.7 million of liabilities for employee severance costs.
The balances at March 31, 2004 for Corporate included approximately $7 million of retirement costs, which were paid in April 2004.
In addition to the above restructuring activities, we are still managing a 2001/2000 restructuring plan associated with customer settlements for the discontinuance of overlapping and nonstrategic products and other product development projects within our Provider Technologies segment.
Customer settlement reserves were established, reviewed and assessed on a customer and contract specific basis, and actual settlements for each customer varied significantly depending on the specific mix and number of products, and each customer contract or contracts.
In 2005, 2004 and 2003, we reversed $4.0 million, $66.4 million and $22.3 million of accrued customer settlement reserves into operating expenses due to favorable settlements and negotiations with affected customers.
There have been no significant offsetting changes in estimates that increase the provision for customer settlements.
Total cash and non-cash settlements of $45.3 million and $95.6 million have been incurred since the inception of this restructuring plan.
Non-cash settlements represent write-offs of customer receivables.
During the third quarter of 2003, we had completed, on a cumulative basis, settlements with 71% of our affected customers.
Additionally, we announced the general availability of a critical software component of our clinical strategy, which helped us refine our estimate of customers expected to move forward with the clinical product replacements and provided a more favorable prognosis of remaining settlements.
Accordingly, we reversed $22.3 million of the customer settlement reserve in the fiscal year.
In 2004, we had significant settlement activity, including the completion and execution of a number of the more difficult customer settlements.
As of March 31, 2004, we were substantially complete (97%) with our customer settlements.
As a result, the customer settlement reserve was reduced by $66.4 million.
The reserves were further reduced by $4.0 million based on favorable settlements finalized as of March 31, 2005.
We do not anticipate additional significant adjustments to the customer settlement reserves.

Tables referenced above, in order (Table 0 first):
<table><tr><td></td><td>2017</td><td>2016</td><td>2015</td></tr><tr><td>Professional Instrumentation</td><td>47%</td><td>46%</td><td>48%</td></tr><tr><td>Industrial Technologies</td><td>53%</td><td>54%</td><td>52%</td></tr></table>
<table><tr><td></td><td colspan="3"> Years Ended March 31,</td></tr><tr><td><i>(Dollars in millions)</i></td><td>2005</td><td>2004</td><td> 2003</td></tr><tr><td>Gross Profit</td><td></td><td></td><td></td></tr><tr><td>Pharmaceutical Solutions</td><td>$2,203.3</td><td>$2,076.9</td><td>$1,956.3</td></tr><tr><td>Medical-Surgical Solutions</td><td>653.6</td><td>603.9</td><td>589.0</td></tr><tr><td>Provider Technologies</td><td>607.8</td><td>567.4</td><td>557.2</td></tr><tr><td>Total</td><td>$3,464.7</td><td>$3,248.2</td><td>$3,102.5</td></tr><tr><td>Gross Profit Margin</td><td></td><td></td><td></td></tr><tr><td>Pharmaceutical Solutions</td><td>2.89%</td><td>3.17%</td><td>3.69%</td></tr><tr><td>Medical-Surgical Solutions</td><td>22.58</td><td>21.49</td><td>20.72</td></tr><tr><td>Provider Technologies</td><td>46.69</td><td>47.19</td><td>45.71</td></tr><tr><td>Total</td><td>4.30</td><td>4.67</td><td>5.43</td></tr></table>
<table><tr><td><i>(Dollars in billions)</i></td><td colspan="2"> 2005</td><td colspan="2"> 2004</td><td colspan="2"> 2003</td></tr><tr><td>Pharmaceutical Solutions</td><td>$76.3</td><td>95%</td><td>$65.5</td><td>94%</td><td>$53.1</td><td>93%</td></tr><tr><td>Medical-Surgical Solutions</td><td>2.9</td><td>4</td><td>2.8</td><td>4</td><td>2.8</td><td>5</td></tr><tr><td>Provider Technologies</td><td>1.3</td><td>1</td><td>1.2</td><td>2</td><td>1.2</td><td>2</td></tr><tr><td>Total</td><td>$80.5</td><td>100%</td><td>$69.5</td><td>100%</td><td>$57.1</td><td>100%</td></tr></table>
<table><tr><td></td><td colspan="2">Pharmaceutical Solutions</td><td colspan="2">Medical-Surgical Solutions</td><td colspan="2">Provider Technologies</td><td colspan="2">Corporate</td><td></td></tr><tr><td></td><td></td><td>Exit-</td><td></td><td>Exit-</td><td></td><td>Exit-</td><td></td><td>Exit-</td><td></td></tr><tr><td><i>(In millions)</i></td><td>Severance</td><td>Related</td><td>Severance</td><td>Related</td><td>Severance</td><td>Related</td><td>Severance</td><td>Related</td><td>Total</td></tr><tr><td> Balance, March 31, 2002</td><td>$1.2</td><td>$4.4</td><td>$10.9</td><td>$14.3</td><td>$5.6</td><td>$4.5</td><td>$16.8</td><td>$0.3</td><td>$58.0</td></tr><tr><td>Current year expenses</td><td>0.8</td><td>1.1</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1.9</td></tr><tr><td>Adjustments to prior years’expenses</td><td>-0.3</td><td>5.1</td><td>-5.5</td><td>-6.5</td><td>—</td><td>—</td><td>-0.8</td><td>—</td><td>-8.0</td></tr><tr><td>Net expense for the period</td><td>0.5</td><td>6.2</td><td>-5.5</td><td>-6.5</td><td>—</td><td>—</td><td>-0.8</td><td>—</td><td>-6.1</td></tr><tr><td>Cash expenditures</td><td>-1.7</td><td>-2.5</td><td>-3.7</td><td>-3.8</td><td>-4.7</td><td>-1.5</td><td>-2.0</td><td>-0.3</td><td>-20.2</td></tr><tr><td> Balance, March 31, 2003</td><td>—</td><td>8.1</td><td>1.7</td><td>4.0</td><td>0.9</td><td>3.0</td><td>14.0</td><td>—</td><td>31.7</td></tr><tr><td>Current year expenses</td><td>0.6</td><td>0.2</td><td>2.0</td><td>0.1</td><td>—</td><td>—</td><td>3.9</td><td>—</td><td>6.8</td></tr><tr><td>Adjustments to prior years’expenses</td><td>—</td><td>-1.3</td><td>-0.4</td><td>-1.1</td><td>—</td><td>-0.2</td><td>-0.3</td><td>—</td><td>-3.3</td></tr><tr><td>Net expense for the period</td><td>0.6</td><td>-1.1</td><td>1.6</td><td>-1.0</td><td>—</td><td>-0.2</td><td>3.6</td><td>—</td><td>3.5</td></tr><tr><td>Cash expenditures</td><td>-0.2</td><td>-1.8</td><td>-1.6</td><td>-1.1</td><td>-0.7</td><td>-0.9</td><td>-7.1</td><td>—</td><td>-13.4</td></tr><tr><td> Balance, March 31, 2004</td><td>0.4</td><td>5.2</td><td>1.7</td><td>1.9</td><td>0.2</td><td>1.9</td><td>10.5</td><td>—</td><td>21.8</td></tr><tr><td>Current year expenses</td><td>—</td><td>0.2</td><td>0.7</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>0.9</td></tr><tr><td>Adjustments to prior years’expenses</td><td>-0.1</td><td>0.5</td><td>-0.2</td><td>-0.2</td><td>—</td><td>-0.4</td><td>—</td><td>—</td><td>-0.4</td></tr><tr><td>Net expense for the period</td><td>-0.1</td><td>0.7</td><td>0.5</td><td>-0.2</td><td>—</td><td>-0.4</td><td>—</td><td>—</td><td>0.5</td></tr><tr><td>Liabilities related to theMMCacquisition</td><td>—</td><td>—</td><td>1.7</td><td>—</td><td>—</td><td>—</td><td>—</td><td>—</td><td>1.7</td></tr><tr><td>Cash expenditures</td><td>-0.3</td><td>-2.6</td><td>-3.0</td><td>-0.6</td><td>—</td><td>-0.5</td><td>-10.0</td><td>—</td><td>-17.0</td></tr><tr><td> Balance, March 31, 2005</td><td>$—</td><td>$3.3</td><td>$0.9</td><td>$1.1</td><td>$0.2</td><td>$1.0</td><td>$0.5</td><td>$—</td><td>$7.0</td></tr></table>

Question: What's the average of the Medical-Surgical Solutions in the years where Medical-Surgical Solutions is positive? (in million)
Answer: 615.5
Reasoning program: add(653.6,603.9), add(#0,589), divide(#1,const_3)